Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
Identifieur interne :
003430 ( PascalFrancis/Curation );
précédent :
003429;
suivant :
003431
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
Auteurs : L. V. Metman [
États-Unis] ;
P. J. Blanchet [
États-Unis] ;
D. De Jong [
États-Unis] ;
M. M. Mouradian [
États-Unis] ;
T. N. Chase [
États-Unis]
Source :
-
Movement disorders [ 0885-3185 ] ; 1996.
RBID : Pascal:96-0244005
Descripteurs français
- Pascal (Inist)
- Parkinson maladie,
Agoniste,
Récepteur dopaminergique D1,
Antagoniste,
Récepteur dopaminergique D2,
Ergoline dérivé,
Traitement,
Chimiothérapie,
Homme,
Antiparkinsonien,
FCE 23884.
- Wicri :
English descriptors
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 11 |
---|
A06 | | | | @2 3 |
---|
A08 | 01 | 1 | ENG | @1 Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
---|
A11 | 01 | 1 | | @1 METMAN (L. V.) |
---|
A11 | 02 | 1 | | @1 BLANCHET (P. J.) |
---|
A11 | 03 | 1 | | @1 DE JONG (D.) |
---|
A11 | 04 | 1 | | @1 MOURADIAN (M. M.) |
---|
A11 | 05 | 1 | | @1 CHASE (T. N.) |
---|
A14 | 01 | | | @1 Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health @2 Bethesda, Maryland @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. |
---|
A20 | | | | @1 257-260 |
---|
A21 | | | | @1 1996 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000043010170050 |
---|
A44 | | | | @0 0000 |
---|
A45 | | | | @0 21 ref. |
---|
A47 | 01 | 1 | | @0 96-0244005 |
---|
A60 | | | | @1 P |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02B06 |
---|
C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
---|
C03 | 02 | X | FRE | @0 Agoniste @5 04 |
---|
C03 | 02 | X | ENG | @0 Agonist @5 04 |
---|
C03 | 02 | X | SPA | @0 Agonista @5 04 |
---|
C03 | 03 | X | FRE | @0 Récepteur dopaminergique D1 @5 05 |
---|
C03 | 03 | X | ENG | @0 D1 Dopamine receptor @5 05 @6 «D1» Dopamine receptor |
---|
C03 | 03 | X | SPA | @0 Receptor dopaminérgico D1 @5 05 |
---|
C03 | 04 | X | FRE | @0 Antagoniste @5 06 |
---|
C03 | 04 | X | ENG | @0 Antagonist @5 06 |
---|
C03 | 04 | X | SPA | @0 Antagonista @5 06 |
---|
C03 | 05 | X | FRE | @0 Récepteur dopaminergique D2 @5 07 |
---|
C03 | 05 | X | ENG | @0 D2 Dopamine receptor @5 07 @6 «D2» Dopamine receptor |
---|
C03 | 05 | X | SPA | @0 Receptor dopaminérgico D2 @5 07 |
---|
C03 | 06 | X | FRE | @0 Ergoline dérivé @2 FR @5 16 |
---|
C03 | 06 | X | ENG | @0 Ergoline derivatives @2 FR @5 16 |
---|
C03 | 07 | X | FRE | @0 Traitement @5 17 |
---|
C03 | 07 | X | ENG | @0 Treatment @5 17 |
---|
C03 | 07 | X | GER | @0 Aufbereiten @5 17 |
---|
C03 | 07 | X | SPA | @0 Tratamiento @5 17 |
---|
C03 | 08 | X | FRE | @0 Chimiothérapie @5 18 |
---|
C03 | 08 | X | ENG | @0 Chemotherapy @5 18 |
---|
C03 | 08 | X | SPA | @0 Quimioterapia @5 18 |
---|
C03 | 09 | X | FRE | @0 Homme @5 20 |
---|
C03 | 09 | X | ENG | @0 Human @5 20 |
---|
C03 | 09 | X | SPA | @0 Hombre @5 20 |
---|
C03 | 10 | X | FRE | @0 Antiparkinsonien @5 23 |
---|
C03 | 10 | X | ENG | @0 Antiparkinson agent @5 23 |
---|
C03 | 10 | X | SPA | @0 Antiparkinsoniano @5 23 |
---|
C03 | 11 | X | FRE | @0 FCE 23884 @2 FR @4 INC @5 86 |
---|
C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
---|
C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
---|
C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
---|
C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
---|
C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
---|
C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
---|
C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
---|
C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
---|
C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
---|
C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
---|
C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
---|
C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
---|
C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
---|
N21 | | | | @1 169 |
---|
|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003394
Links to Exploration step
Pascal:96-0244005
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of the putative dopamine D<sub>1</sub>
agonist and D<sub>2</sub>
antagonist FCE 23884 on Parkinson's disease</title>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0244005</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0244005 INIST</idno>
<idno type="RBID">Pascal:96-0244005</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003394</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003430</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of the putative dopamine D<sub>1</sub>
agonist and D<sub>2</sub>
antagonist FCE 23884 on Parkinson's disease</title>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>D1 Dopamine receptor</term>
<term>D2 Dopamine receptor</term>
<term>Ergoline derivatives</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D1</term>
<term>Antagoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Ergoline dérivé</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
<term>FCE 23884</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of the putative dopamine D<sub>1</sub>
agonist and D<sub>2</sub>
antagonist FCE 23884 on Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>METMAN (L. V.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BLANCHET (P. J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DE JONG (D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MOURADIAN (M. M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHASE (T. N.)</s1>
</fA11>
<fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>257-260</s1>
</fA20>
<fA21><s1>1996</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000043010170050</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>96-0244005</s0>
</fA47>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Agonist</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Agonista</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique D1</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>D1 Dopamine receptor</s0>
<s5>05</s5>
<s6>«D1» Dopamine receptor</s6>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico D1</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>07</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ergoline dérivé</s0>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ergoline derivatives</s0>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>FCE 23884</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>169</s1>
</fN21>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003430 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003430 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:96-0244005
|texte= Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | ![](Common/icons/LogoDilib.gif) |